Pfizer’s Metsera deal secures fast-working amylin analog 

In addition to a long-acting GLP-1 that could rival Lilly’s Zepbound, Pfizer’s $10 billion Metsera buyout secures an amylin analog whose early data suggest faster weight loss than both Zepbound and Lilly’s bar-setting amylin therapy eloralintide.

A dose of 1.2 mg of the amylin analog, MET-233i, reduced weight 3.5 times faster than a 15 mg dose of the blockbuster Zepbound tirzepatide and 2.5 times faster than a 9 mg dose of amylin agonist eloralintide, with MET-233i leading to a placebo-adjusted weight loss of 8.4% by four weeks compared with about 14 weeks and 10 weeks, respectively, for the two products from Eli Lilly and Co. (NYSE:LLY). All three products were dosed once weekly...